

Garrett M Brodeur

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5612176/publications.pdf>

Version: 2024-02-01

127
papers

17,684
citations

36691

53
h-index

21239

119
g-index

130
all docs

130
docs citations

130
times ranked

12917
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuroblastoma: biological insights into a clinical enigma. <i>Nature Reviews Cancer</i> , 2003, 3, 203-216.	12.8	1,871
2	Association of Multiple Copies of the N- <i>myc</i> Oncogene with Rapid Progression of Neuroblastomas. <i>New England Journal of Medicine</i> , 1985, 313, 1111-1116.	13.9	1,853
3	Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid. <i>New England Journal of Medicine</i> , 1999, 341, 1165-1173.	13.9	1,722
4	The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report. <i>Journal of Clinical Oncology</i> , 2009, 27, 289-297.	0.8	1,540
5	Identification of ALK as a major familial neuroblastoma predisposition gene. <i>Nature</i> , 2008, 455, 930-935.	13.7	1,207
6	The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report. <i>Journal of Clinical Oncology</i> , 2009, 27, 298-303.	0.8	869
7	Association between High Levels of Expression of the TRK Gene and Favorable Outcome in Human Neuroblastoma. <i>New England Journal of Medicine</i> , 1993, 328, 847-854.	13.9	639
8	Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. <i>New England Journal of Medicine</i> , 2005, 353, 2243-2253.	13.9	495
9	A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene. <i>Molecular Cancer Research</i> , 2008, 6, 735-742.	1.5	298
10	Trk Receptor Expression and Inhibition in Neuroblastomas. <i>Clinical Cancer Research</i> , 2009, 15, 3244-3250.	3.2	258
11	Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. <i>Oncogene</i> , 1999, 18, 4948-4957.	2.6	228
12	Mechanisms of neuroblastoma regression. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 704-713.	12.5	228
13	Biologic Factors Determine Prognosis in Infants With Stage IV Neuroblastoma: A Prospective Children's Cancer Group Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 1260-1268.	0.8	212
14	Biology and Genetics of Human Neuroblastomas. <i>The American Journal of Pediatric Hematology/Oncology</i> , 1997, 19, 93-101.	1.3	205
15	Opsoclonus-myooclonus-ataxia syndrome in neuroblastoma: Clinical outcome and antineuronal antibodies? a report from the children's cancer group study. <i>Medical and Pediatric Oncology</i> , 2001, 36, 612-622.	1.0	203
16	Resistance to chemotherapy mediated by TrkB in neuroblastomas. <i>Cancer Research</i> , 2002, 62, 6462-6.	0.4	182
17	Integrative Genomics Identifies Distinct Molecular Classes of Neuroblastoma and Shows That Multiple Genes Are Targeted by Regional Alterations in DNA Copy Number. <i>Cancer Research</i> , 2006, 66, 6050-6062.	0.4	178
18	Molecular biology and genetics of human neuroblastoma. <i>Cancer Genetics and Cytogenetics</i> , 1989, 41, 153-174.	1.0	176

#	ARTICLE	IF	CITATIONS
19	Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. <i>Oncogene</i> , 2000, 19, 4604-4610.	2.6	169
20	Retinoblastoma and Neuroblastoma Predisposition and Surveillance. <i>Clinical Cancer Research</i> , 2017, 23, e98-e106.	3.2	166
21	CHD5 , a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas. <i>Journal of the National Cancer Institute</i> , 2008, 100, 940-949.	3.0	164
22	Spontaneous regression of neuroblastoma. <i>Cell and Tissue Research</i> , 2018, 372, 277-286.	1.5	149
23	Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. <i>Oncogene</i> , 2005, 24, 2684-2694.	2.6	147
24	Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children's Cancer Group Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 1888-1899.	0.8	146
25	CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. <i>Oncogene</i> , 2003, 22, 1002-1011.	2.6	145
26	Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome. <i>Clinical Cancer Research</i> , 2017, 23, e62-e67.	3.2	139
27	Hyperdiploidy Plus Nonamplified MYCN Confers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 6466-6473.	0.8	135
28	Neuroblastoma: Effect of genetic factors on prognosis and treatment. <i>Cancer</i> , 1992, 70, 1685-1694.	2.0	134
29	Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors. <i>Cancer</i> , 2001, 92, 2699-2708.	2.0	132
30	Pediatric Cancer Predisposition and Surveillance: An Overview, and a Tribute to Alfred G. Knudson Jr. <i>Clinical Cancer Research</i> , 2017, 23, e1-e5.	3.2	130
31	Molecular Basis of Clinical Heterogeneity in Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 1992, 14, 111-116.	0.3	127
32	Expression of TrkA, TrkB and TrkC in human neuroblastomas. <i>Journal of Neuro-Oncology</i> , 1997, 31, 49-56.	1.4	127
33	Proliferation of Human Neuroblastomas Mediated by the Epidermal Growth Factor Receptor. <i>Cancer Research</i> , 2005, 65, 9868-9875.	0.4	122
34	Expression of the Neurotrophin Receptor TrkB Is Associated With Unfavorable Outcome in Wilms' Tumor. <i>Journal of Clinical Oncology</i> , 2001, 19, 689-696.	0.8	99
35	Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2). <i>Genomics</i> , 1995, 25, 538-546.	1.3	88
36	Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells. <i>Oncogene</i> , 2000, 19, 2043-2051.	2.6	86

#	ARTICLE	IF	CITATIONS
37	Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. <i>Cancer Research</i> , 2002, 62, 1802-8.	0.4	81
38	Role of <i>CHD5</i> in Human Cancers: 10 Years Later. <i>Cancer Research</i> , 2014, 74, 652-658.	0.4	77
39	Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1057-1065.	1.1	76
40	Outcomes of Children With Intermediate-Risk Neuroblastoma After Treatment Stratified by MYCN Status and Tumor Cell Ploidy. <i>Journal of Clinical Oncology</i> , 2005, 23, 8819-8827.	0.8	74
41	CHD5 is required for spermiogenesis and chromatin condensation. <i>Mechanisms of Development</i> , 2014, 131, 35-46.	1.7	69
42	Clinical implications of oncogene activation in human neuroblastomas. <i>Cancer</i> , 1986, 58, 541-545.	2.0	68
43	Clinical Significance of <i>MYCN</i> Amplification and Ploidy in Favorable-Stage Neuroblastoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 913-918.	0.8	67
44	Preferential amplification of the paternal allele of the <i>myc</i> gene in human neuroblastomas. <i>Nature Genetics</i> , 1993, 4, 191-194.	9.4	65
45	Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. <i>Cancer Research</i> , 2002, 62, 6651-8.	0.4	65
46	Comprehensive analysis of chromosome 1p deletions in neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2001, 36, 32-36.	1.0	63
47	Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. <i>Cancer Letters</i> , 2016, 372, 179-186.	3.2	63
48	Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. <i>Medical and Pediatric Oncology</i> , 2000, 35, 603-607.	1.0	61
49	Mechanisms of CHD5 Inactivation in Neuroblastomas. <i>Clinical Cancer Research</i> , 2012, 18, 1588-1597.	3.2	60
50	A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma. <i>Clinical Cancer Research</i> , 2012, 18, 2012-2023.	3.2	59
51	Identification of patient subgroups with markedly disparate rates of <i>MYCN</i> amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. <i>Cancer</i> , 2016, 122, 935-945.	2.0	58
52	Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma. <i>Genes Chromosomes and Cancer</i> , 1995, 14, 196-203.	1.5	56
53	Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma. <i>Clinical Cancer Research</i> , 2010, 16, 1478-1485.	3.2	56
54	The <i>neuro</i> of neuroblastoma: <i>Neuroblastoma</i> as a neurodevelopmental disorder. <i>Annals of Neurology</i> , 2016, 80, 13-23.	2.8	54

#	ARTICLE	IF	CITATIONS
55	Correlation between morphologic and other prognostic markers of neuroblastoma a study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the pediatric oncology group. <i>Cancer</i> , 1993, 71, 3173-3181.	2.0	53
56	Epigenetic silencing of <i>CHD5</i> , a novel tumor suppressor gene, occurs in early colorectal cancer stages. <i>Cancer</i> , 2014, 120, 172-180.	2.0	51
57	Novel regions of chromosomal loss in familial neuroblastoma by comparative genomic hybridization. , 1997, 19, 176-184.		48
58	Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2001, 36, 24-27.	1.0	48
59	Human neuroblastoma cell lines that express N-myc without gene amplification. <i>Cancer</i> , 1993, 72, 3346-3354.	2.0	43
60	Therapeutic targets for neuroblastomas. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 277-292.	1.5	43
61	Familial neuroblastoma: A three-generation pedigree and a further association with Hirschsprung disease. , 1997, 28, 1-5.		40
62	High-Resolution Mapping of a 130-kb Core Region of the MYCN Amplicon in Neuroblastomas. <i>Genomics</i> , 1996, 32, 97-103.	1.3	39
63	Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas. <i>Medical and Pediatric Oncology</i> , 2000, 35, 544-546.	1.0	37
64	Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy. <i>Biomaterials</i> , 2015, 51, 22-29.	5.7	36
65	The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex. <i>Biochemical Journal</i> , 2015, 468, 345-352.	1.7	36
66	Neuroblastoma -Clinical Applications of Molecular Parameters. <i>Brain Pathology</i> , 1990, 1, 47-54.	2.1	34
67	Clinical significance of <i>NTRK</i> family gene expression in neuroblastomas. <i>Pediatric Blood and Cancer</i> , 2012, 59, 226-232.	0.8	33
68	Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma. <i>Cancer Letters</i> , 2015, 360, 205-212.	3.2	32
69	TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 131-141.	1.1	32
70	Diagnosis of Beckwith-Wiedemann syndrome in children presenting with Wilms tumor. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27296.	0.8	32
71	Expression of neurotrophin receptor TrkA inhibits angiogenesis in neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2000, 35, 569-572.	1.0	31
72	Relative Quantitative RT-PCR Protocol for <i>TrkB</i> Expression in Neuroblastoma Using <i>GAPD</i> as an Internal Control. <i>BioTechniques</i> , 2000, 28, 681-691.	0.8	31

#	ARTICLE	IF	CITATIONS
73	Use of the single-strand conformation polymorphism technique to detect loss of heterozygosity in neuroblastoma. <i>Genes Chromosomes and Cancer</i> , 1993, 7, 102-108.	1.5	29
74	Autoregulation of the human N-myc oncogene is disrupted in amplified but not single-copy neuroblastoma cell lines. <i>Oncogene</i> , 1997, 15, 1937-1946.	2.6	29
75	The Future of Surveillance in the Context of Cancer Predisposition: Through the Murky Looking Glass. <i>Clinical Cancer Research</i> , 2017, 23, e133-e137.	3.2	29
76	p75 mediated apoptosis in neuroblastoma cells is inhibited by expression of TrkA. <i>Medical and Pediatric Oncology</i> , 2000, 35, 573-576.	1.0	27
77	The effect of P75 on Trk receptors in neuroblastomas. <i>Cancer Letters</i> , 2011, 305, 76-85.	3.2	27
78	Molecular characterization and chromosomal localization of DRT (EPHT3): a developmentally regulated human protein-tyrosine kinase gene of the EPH family. <i>Human Molecular Genetics</i> , 1995, 4, 2033-2045.	1.4	26
79	Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. <i>Medical and Pediatric Oncology</i> , 2000, 35, 526-530.	1.0	26
80	Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing <i>SMAD4</i> / <i>BMPR1A</i> Variant. <i>Cancer Prevention Research</i> , 2021, 14, 215-222.	0.7	26
81	Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. <i>Medical and Pediatric Oncology</i> , 2000, 35, 512-515.	1.0	25
82	Prognostic significance of EPHB6, EFNB2, and EFNB3 expressions in neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2000, 35, 656-658.	1.0	25
83	Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model. <i>Clinical Cancer Research</i> , 2018, 24, 2585-2593.	3.2	25
84	The effectiveness of Wilms tumor screening in Beckwith-Wiedemann spectrum. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3115-3123.	1.2	25
85	MYCN is the only highly expressed gene from the core amplified domain in human neuroblastomas. , 1998, 23, 134-140.		22
86	AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 477-486.	1.1	22
87	Management of adrenal masses in patients with Beckwith-Wiedemann syndrome. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26432.	0.8	22
88	Retinoic acid-induced CHD5 upregulation and neuronal differentiation of neuroblastoma. <i>Molecular Cancer</i> , 2015, 14, 150.	7.9	21
89	Role of microRNAs in epigenetic silencing of the <i>CHD5</i> tumor suppressor gene in neuroblastomas. <i>Oncotarget</i> , 2016, 7, 15977-15985.	0.8	20
90	Comprehensive evaluation of context dependence of the prognostic impact of <i>MYCN</i> amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27819.	0.8	20

#	ARTICLE	IF	CITATIONS
91	Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas. <i>Medical and Pediatric Oncology</i> , 2001, 36, 80-82.	1.0	19
92	Development of subnanomolar radiofluorinated (2-pyrrolidin-1-yl)imidazo[1,2-b]pyridazine pan-Trk inhibitors as candidate PET imaging probes. <i>MedChemComm</i> , 2015, 6, 2184-2193.	3.5	19
93	Earlier Colorectal Cancer Screening May Be Necessary In Patients With Li-Fraumeni Syndrome. <i>Gastroenterology</i> , 2019, 156, 273-274.	0.6	19
94	Significance of intratumoral genetic heterogeneity in neuroblastomas. <i>Medical and Pediatric Oncology</i> , 2002, 38, 112-113.	1.0	18
95	Different effects of TrkA expression in neuroblastoma cell lines with or without MYCN amplification. <i>Medical and Pediatric Oncology</i> , 2000, 35, 623-627.	1.0	17
96	Analysis of genomic imprinting at 1p35-36 in neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2001, 36, 52-55.	1.0	16
97	Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1469-1475.	1.1	16
98	Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 920-926.	1.9	15
99	Biological aspects of neuroblastoma screening. <i>Medical and Pediatric Oncology</i> , 1998, 31, 394-400.	1.0	14
100	<p>A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 4305-4319.	2.0	13
101	TrkA signal transduction pathways in neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2001, 36, 108-110.	1.0	11
102	Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10536-10536.	0.8	10
103	A variant transcript encoding an isoform of the human protein tyrosine kinase EPHB2 is generated by alternative splicing and alternative use of polyadenylation signals. <i>Oncogene</i> , 1998, 17, 521-526.	2.6	9
104	Gain-of-Function STAT1 Mutation With Familial Lymphadenopathy and Hodgkin Lymphoma. <i>Frontiers in Pediatrics</i> , 2019, 7, 160.	0.9	9
105	Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors. <i>Cancer Research</i> , 2020, 80, 4258-4265.	0.4	9
106	Biology of tumors of the peripheral nervous system. <i>Cancer and Metastasis Reviews</i> , 1991, 10, 321-333.	2.7	8
107	Do the ends justify the means?. <i>Nature Medicine</i> , 1995, 1, 203-205.	15.2	8
108	Rotary bioreactor culture can discern specific behavior phenotypes in Trk-null and Trk-expressing neuroblastoma cell lines. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2014, 50, 188-193.	0.7	8

#	ARTICLE	IF	CITATIONS
109	Schwann cell-conditioned medium inhibits angiogenesis in vitro and in vivo. <i>Medical and Pediatric Oncology</i> , 2000, 35, 590-592.	1.0	6
110	Pediatric Somatic Tumor Sequencing Identifies Underlying Cancer Predisposition. <i>JCO Precision Oncology</i> , 2019, 3, 1-26.	1.5	6
111	The Clinical Spectrum of PTEN Hamartoma Tumor Syndrome: Exploring the Value of Thyroid Surveillance. <i>Hormone Research in Paediatrics</i> , 2020, 93, 634-642.	0.8	6
112	RET receptor expression and interaction with TRK receptors in neuroblastomas. <i>Oncology Reports</i> , 2020, 44, 263-272.	1.2	6
113	Getting Into the AKT. <i>Journal of the National Cancer Institute</i> , 2010, 102, 747-749.	3.0	5
114	Poloxamer-linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of high-risk neuroblastoma with primary and acquired chemoresistance. <i>FASEB Journal</i> , 2022, 36, e22213.	0.2	5
115	Knowing Your ABCCs: Novel Functions of ABCC Transporters. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1207-1208.	3.0	4
116	Nanomicellar Lenalidomide-Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 6873-6886.	3.3	4
117	Environment-Sensitive Polymeric Micelles Encapsulating SN-38 Potently Suppress Growth of Neuroblastoma Cells Exhibiting Intrinsic and Acquired Drug Resistance. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 240-247.	2.5	4
118	Molecular Analysis of Gene Amplification in Tumors. <i>Current Protocols in Human Genetics</i> , 1994, 2, Unit 10.5.	3.5	3
119	Role of Apoptosis in Human Neuroblastomas. , 1999, , 305-318.		3
120	Nanocarrier-Based Delivery of SN22 as a Tocopheryl Oxamate Prodrug Achieves Rapid Tumor Regression and Extends Survival in High-Risk Neuroblastoma Models. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1752.	1.8	3
121	p75 mediated apoptosis in neuroblastoma cells is inhibited by expression of TrkA. , 2000, 35, 573.		2
122	Biological aspects of neuroblastoma screening. <i>Medical and Pediatric Oncology</i> , 1998, 31, 394-400.	1.0	1
123	Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors. , 2001, 92, 2699.		1
124	Significance of intratumoral genetic heterogeneity in neuroblastomas. , 2002, 38, 112.		1
125	Identifying TRKA and TRKB specific pathways in neuroblastoma through phosphoproteomic analysis.. <i>Journal of Clinical Oncology</i> , 2012, 30, e20008-e20008.	0.8	0
126	Colorectal cancer risk in Li-Fraumeni syndrome: Is it time for earlier surveillance?. <i>Journal of Clinical Oncology</i> , 2018, 36, e13503-e13503.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Abstract 5898: Bone morphogenic protein receptor 2 (<i>BMPR2</i>) as a potential germline driver in Juvenile Polyposis Syndrome (JPS). <i>Cancer Research</i> , 2022, 82, 5898-5898.	0.4	0